Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 9:13:1077468.
doi: 10.3389/fphar.2022.1077468. eCollection 2022.

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Zherui Liu  1   2 , Yun Zhu  1 , Huan Xie  1 , Zhengsheng Zou  1   2   1
Affiliations
Review

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Zherui Liu et al. Front Pharmacol. .

Abstract

In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded indication and increased use of Immune checkpoint inhibitors have resulted in increased reports of toxicity called immune-related adverse events (irAEs). Due to the unique immunological characteristics of the liver, a hepatic immune-related adverse events has also been reported, which is usually termed Immune-mediated hepatitis (IMH). So far, it is generally considered that the mechanism of IMH induced by Immune checkpoint inhibitors is mainly the overactivation of T cells. It has been reported that the incidence of IMH ranges from 1% to 15%. Because of the lack of specific markers, a diagnosis of exclusion of IMH is critical. Although most IMH is mild and recoverable, several death cases have been reported, which has been increasingly concerned. This review summarizes the current understanding of the pathophysiology, epidemiology, diagnosis, management and prognosis of IMH caused by Immune checkpoint inhibitors. It also discusses the controversial issues in IMH, such as the role of liver biopsy, grading criteria, risk factors, rational treatment strategies with steroids, and the timing of Immune checkpoint inhibitors rechallenging, which may provide helpful information for IMH in future clinical practice.

Keywords: cancer; drug-induced liver injury; hepatitis; immune checkpoint inhibitors; immune-related adverse events; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Mechanisms of T cells activation and immune-mediated hepatitis caused by ICIs. (A) Blockade of CTLA-4 activates T cells at the priming phase. (B) Further anti-tumor effect induced by the blockade of PD-1 and PD-L1 occurs in the effector phase. Once liver self-tolerance impairs, immune cells such as (C) Th cells, (D) Monocytes, (E) Treg cells, and (F) cytotoxic T cells will be involved in the pathophysiological process of immune-mediated hepatitis.
FIGURE 2
FIGURE 2
Management for immune-mediated hepatitis caused by immune checkpoint inhibitors. LFT, liver function test; ICI, immune checkpoint inhibitor; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBil, total bilirubin; ULN, upper limit of normal; BLV, baseline value; MMF, mycophenolate mofetil; UDCA, ursodeoxycholic acid; ATG, antithymocyte globulin; AZA, azathioprine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aamdal E., Jacobsen K. D., Straume O., Kersten C., Herlofsen O., Karlsen J., et al. (2022). Ipilimumab in a real-world population: A prospective phase IV trial with long-term follow-up. Int. J. Cancer 150, 100–111. 10.1002/ijc.33768 - DOI - PubMed
    1. Abdel-Wahab N., Shah M., Lopez-Olivo M. A., Suarez-Almazor M. E. (2018). Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann. Intern Med. 168, 121–130. 10.7326/M17-2073 - DOI - PubMed
    1. Abu-Sbeih H., Tang T., Ali F. S., Johnson D. H., Qiao W., Diab A., et al. (2018). The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J. Immunother. Precis. Oncol. 1, 7–18. 10.4103/jipo.Jipo_12_18 - DOI
    1. Ahmed T., Pandey R., Shah B., Black J. (2015). Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep. 2015, bcr2014208102. 10.1136/bcr-2014-208102 - DOI - PMC - PubMed
    1. Ascierto P. A., Del Vecchio M., Robert C., Mackiewicz A., Chiarion-Sileni V., Arance A., et al. (2017). Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 18, 611–622. 10.1016/S1470-2045(17)30231-0 - DOI - PubMed

Grants and funding

This study was supported by grants from the 302 Hospital Foundation (No. YNKTZ2018001), National Natural Science Foundation of China (No. 81670527).